AU2018263159A1 - Methods of selectively treating asthma using IL-17 antagonists - Google Patents

Methods of selectively treating asthma using IL-17 antagonists Download PDF

Info

Publication number
AU2018263159A1
AU2018263159A1 AU2018263159A AU2018263159A AU2018263159A1 AU 2018263159 A1 AU2018263159 A1 AU 2018263159A1 AU 2018263159 A AU2018263159 A AU 2018263159A AU 2018263159 A AU2018263159 A AU 2018263159A AU 2018263159 A1 AU2018263159 A1 AU 2018263159A1
Authority
AU
Australia
Prior art keywords
seq
patient
antagonist
antibody
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018263159A
Other languages
English (en)
Inventor
Sarah Schmidt GRANT
Shamsah KAZANI
Edward KHOKHLOVICH
Jason LARAMIE
Robert Martin STRIETER
Tricia Ann THORNTON-WELLS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018263159A1 publication Critical patent/AU2018263159A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018263159A 2017-05-05 2018-05-04 Methods of selectively treating asthma using IL-17 antagonists Abandoned AU2018263159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (1)

Publication Number Publication Date
AU2018263159A1 true AU2018263159A1 (en) 2019-11-07

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018263159A Abandoned AU2018263159A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using IL-17 antagonists

Country Status (13)

Country Link
US (1) US10676522B2 (enExample)
EP (1) EP3619536A1 (enExample)
JP (1) JP2020518604A (enExample)
KR (1) KR20190142398A (enExample)
CN (1) CN110582702A (enExample)
AU (1) AU2018263159A1 (enExample)
BR (1) BR112019023141A2 (enExample)
CA (1) CA3062179A1 (enExample)
CL (1) CL2019003161A1 (enExample)
MX (1) MX2019013160A (enExample)
RU (1) RU2019139387A (enExample)
TW (1) TW201842933A (enExample)
WO (1) WO2018203289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP2023521909A (ja) * 2020-04-17 2023-05-25 イーライ リリー アンド カンパニー 呼吸器疾患の治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20110123530A1 (en) * 2008-03-31 2011-05-26 Arron Joseph R Compositions and methods for treating and diagnosing asthma
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
AU2014340129A1 (en) * 2013-10-23 2016-05-26 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
US20160000936A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
CN110582702A (zh) 2019-12-17
US20180319881A1 (en) 2018-11-08
US10676522B2 (en) 2020-06-09
TW201842933A (zh) 2018-12-16
MX2019013160A (es) 2020-02-05
EP3619536A1 (en) 2020-03-11
BR112019023141A2 (pt) 2020-07-28
CA3062179A1 (en) 2018-11-08
CL2019003161A1 (es) 2020-02-07
JP2020518604A (ja) 2020-06-25
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07
WO2018203289A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
JP2025106377A (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
US20230235069A1 (en) Treatment of atopic dermatitis
JP7589045B2 (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
US10676522B2 (en) Methods of selectively treating asthma using IL-17 antagonists
JP2023505215A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
US11964005B2 (en) Methods of treating atopic dermatitis
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
WO2025210099A1 (en) Method of treatment and selecting a subject
WO2025120567A1 (en) Method of treatment of asthma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted